,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationMean,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Morris Corporate Center 1,Building C 300 Interpace Parkway,Parsippany,NJ,07054,United States,855 776 6419,https://www.interpace.com,Diagnostics & Research,Healthcare,"Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.",94,"{'maxAge': 1, 'name': 'Dr. Thomas W. Burnell Ph.D.', 'age': 60, 'title': 'Pres, CEO & Director', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 634169, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.15,1.15,1.15,1.15,1.15,1.15,1.15,1.15,0.0,0.628284,-7.666666,691,691,13256,8798,8798,0.0,0.0,800,800,4961353,0.51,3.54,0.13275233,1.63355,1.3478075,0.0,0.0,USD,61314348,-0.40794,3206757,4314220,47355,68563,1610668800,1613088000,0.0117,0.28605,0.0,0.19,0.0117999995,-14.428,1672444800,1703980800,1688083200,-1838000,-0.44,-0.15,1:10,1579046400,1.641,23.83,PNK,EQUITY,IDXG,IDXG,"Interpace Biosciences, Inc.","Interpace Biosciences, Inc.",895671000,America/New_York,EDT,-14400000,1.15,3.0,hold,5079000,1.177,2573000,14896000,0.782,0.957,37373000,8.726,0.02115,18231000,-137750,-1976000,0.491,0.60356,0.06885,0.02328,USD,
1,Morris Corporate Center 1,Building C 300 Interpace Parkway,Parsippany,NJ,07054,United States,855 776 6419,https://www.interpace.com,Diagnostics & Research,Healthcare,"Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.",94,"{'maxAge': 1, 'name': 'Mr. Christopher  McCarthy', 'age': 30, 'title': 'Chief Financial Officer', 'yearBorn': 1992, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.15,1.15,1.15,1.15,1.15,1.15,1.15,1.15,0.0,0.628284,-7.666666,691,691,13256,8798,8798,0.0,0.0,800,800,4961353,0.51,3.54,0.13275233,1.63355,1.3478075,0.0,0.0,USD,61314348,-0.40794,3206757,4314220,47355,68563,1610668800,1613088000,0.0117,0.28605,0.0,0.19,0.0117999995,-14.428,1672444800,1703980800,1688083200,-1838000,-0.44,-0.15,1:10,1579046400,1.641,23.83,PNK,EQUITY,IDXG,IDXG,"Interpace Biosciences, Inc.","Interpace Biosciences, Inc.",895671000,America/New_York,EDT,-14400000,1.15,3.0,hold,5079000,1.177,2573000,14896000,0.782,0.957,37373000,8.726,0.02115,18231000,-137750,-1976000,0.491,0.60356,0.06885,0.02328,USD,
2,Morris Corporate Center 1,Building C 300 Interpace Parkway,Parsippany,NJ,07054,United States,855 776 6419,https://www.interpace.com,Diagnostics & Research,Healthcare,"Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.",94,"{'maxAge': 1, 'name': 'Dr. Sydney D. Finkelstein', 'title': 'Chief Scientific Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.15,1.15,1.15,1.15,1.15,1.15,1.15,1.15,0.0,0.628284,-7.666666,691,691,13256,8798,8798,0.0,0.0,800,800,4961353,0.51,3.54,0.13275233,1.63355,1.3478075,0.0,0.0,USD,61314348,-0.40794,3206757,4314220,47355,68563,1610668800,1613088000,0.0117,0.28605,0.0,0.19,0.0117999995,-14.428,1672444800,1703980800,1688083200,-1838000,-0.44,-0.15,1:10,1579046400,1.641,23.83,PNK,EQUITY,IDXG,IDXG,"Interpace Biosciences, Inc.","Interpace Biosciences, Inc.",895671000,America/New_York,EDT,-14400000,1.15,3.0,hold,5079000,1.177,2573000,14896000,0.782,0.957,37373000,8.726,0.02115,18231000,-137750,-1976000,0.491,0.60356,0.06885,0.02328,USD,
3,Morris Corporate Center 1,Building C 300 Interpace Parkway,Parsippany,NJ,07054,United States,855 776 6419,https://www.interpace.com,Diagnostics & Research,Healthcare,"Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.",94,"{'maxAge': 1, 'name': 'Mr. Jody  Campbell', 'title': 'Chief Revenue Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.15,1.15,1.15,1.15,1.15,1.15,1.15,1.15,0.0,0.628284,-7.666666,691,691,13256,8798,8798,0.0,0.0,800,800,4961353,0.51,3.54,0.13275233,1.63355,1.3478075,0.0,0.0,USD,61314348,-0.40794,3206757,4314220,47355,68563,1610668800,1613088000,0.0117,0.28605,0.0,0.19,0.0117999995,-14.428,1672444800,1703980800,1688083200,-1838000,-0.44,-0.15,1:10,1579046400,1.641,23.83,PNK,EQUITY,IDXG,IDXG,"Interpace Biosciences, Inc.","Interpace Biosciences, Inc.",895671000,America/New_York,EDT,-14400000,1.15,3.0,hold,5079000,1.177,2573000,14896000,0.782,0.957,37373000,8.726,0.02115,18231000,-137750,-1976000,0.491,0.60356,0.06885,0.02328,USD,
4,Morris Corporate Center 1,Building C 300 Interpace Parkway,Parsippany,NJ,07054,United States,855 776 6419,https://www.interpace.com,Diagnostics & Research,Healthcare,"Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.",94,"{'maxAge': 1, 'name': 'Mr. Patrick  Kane', 'title': 'VP & Corp. Controller', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.15,1.15,1.15,1.15,1.15,1.15,1.15,1.15,0.0,0.628284,-7.666666,691,691,13256,8798,8798,0.0,0.0,800,800,4961353,0.51,3.54,0.13275233,1.63355,1.3478075,0.0,0.0,USD,61314348,-0.40794,3206757,4314220,47355,68563,1610668800,1613088000,0.0117,0.28605,0.0,0.19,0.0117999995,-14.428,1672444800,1703980800,1688083200,-1838000,-0.44,-0.15,1:10,1579046400,1.641,23.83,PNK,EQUITY,IDXG,IDXG,"Interpace Biosciences, Inc.","Interpace Biosciences, Inc.",895671000,America/New_York,EDT,-14400000,1.15,3.0,hold,5079000,1.177,2573000,14896000,0.782,0.957,37373000,8.726,0.02115,18231000,-137750,-1976000,0.491,0.60356,0.06885,0.02328,USD,
